Boundless Bio (BOLD) Financials

Boundless Bio remains a pre-revenue biotechnology company with persistent operating losses. Revenue and gross profit were reported at zero in every income statement provided. Net losses remained substantial, ranging from $12.1 million to $17.0 million in the quarterly data, with a $13.6 million loss in Q1 2026, compared with $12.9 million in Q4 2025 and $15.8 million in Q1 2025.

There are some signs of cost control. Total operating expenses declined from $19.4 million in Q2 2024 to $14.0 million in Q4 2025 before rising modestly to $14.5 million in Q1 2026. Research and development expense also fell to $9.7 million in Q1 2026 from $14.7 million in Q2 2024. However, these reductions have not yet translated into profitability or positive operating cash flow.

Liquidity is currently the company’s primary financial strength. At March 31, 2026, Boundless Bio held $17.5 million in cash and $75.4 million in short-term investments, or approximately $92.8 million in combined liquid resources. With Q1 operating cash burn of $15.0 million, that balance represents roughly six quarters of liquidity at the latest quarterly burn rate, before considering changes in spending, clinical development, investment income or additional financing.

• Strong near-term liquidity: Cash and short-term investments totaled approximately $92.8 million at the end of Q1 2026, providing an important funding cushion for ongoing research and development.
• Operating expenses have generally trended lower: Quarterly operating expenses fell from $19.4 million in Q2 2024 to $14.5 million in Q1 2026, despite a modest sequential increase from Q4 2025.
• R&D spending has been reduced: Research and development expense declined to $9.7 million in Q1 2026 from more than $14 million in several 2024 quarters, which could extend the company’s cash runway if maintained.
• Limited capital spending: Purchases of property, plant and equipment were only $8,000 in Q1 2026, indicating that the company is not currently consuming significant cash through physical infrastructure investments.
• Interest income provides partial support: Investment income contributed $920,000 in Q1 2026, offsetting a portion of the operating loss and reflecting the company’s sizable investment portfolio.
• Financing activity has been minimal recently: Boundless Bio reported no common-equity issuance in Q1 2026 and only $24,000 of financing cash inflow in Q4 2025. This limits near-term dilution but also means the company is relying primarily on existing resources.
• Share count has been relatively stable: Basic weighted-average shares increased from 22.0 million in Q2 2024 to 22.4 million in Q1 2026, suggesting limited recent dilution in the income statement data.
• No revenue has been reported: The company generated zero revenue in each provided income statement, leaving investment income and existing cash reserves as the main sources of financial support.
• Operating cash flow remains consistently negative: Boundless Bio used $15.0 million in operating cash in Q1 2026, following quarterly operating outflows of $10.1 million to $14.5 million in the preceding periods. The business is not yet funding its operations internally.
• Accumulated losses continue to erode retained earnings: Retained earnings declined to negative $273.2 million at March 31, 2026, compared with negative $151.5 million at March 31, 2024, highlighting the company’s long history of losses and dependence on external capital.

Overall, Boundless Bio’s balance sheet appears capable of supporting operations in the near term, but the company remains financially dependent on its cash reserves and investment portfolio. The key risks for shareholders are the absence of revenue, continued clinical-development spending and the possibility that future funding needs could lead to equity dilution or other financing pressure. Investors should also note that several historical figures are marked as calculated or restated, so comparisons across periods should be interpreted with care.